Podcasts

Recent Episodes

Chandler Park, MD; Pashtoon Kasi, MD, MS

September 25, 2026

Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management

Nataliya Uboha, MD, PhD, discusses zanidatamab-based regimens, their recent approval, and the HERIZON-GEA-01 trial in gastric cancer.

September 24, 2026

Breaking Down the FDA Approval of Zanidatamab-Based Regimens in HER2+ Gastric Cancer

Narjust Florez, MD, and Jonathan Wesley Riess, MD, MS

September 24, 2026

Recent Data Readouts Help Untangle HER2 Overexpression and Mutation Implications in NSCLC

September 23, 2026

INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management

September 22, 2026

Integrating Precision Pathways in HER2+ Gastroesophageal Adenocarcinoma—Testing, Treatment, and Supportive Care

September 21, 2026

Pancreatic Cancer Experts Map Treatment Sequencing With Liposomal Irinotecan and Beyond

September 17, 2026

Fast-Moving Treatment Advances Shape B-Cell Lymphoma Care

Sara Nunnery, MD, MSCI; Matthew Kurian, MD

September 15, 2026

Oncology's AI Adoption Hinges on Weighing Benefits vs Risks and Confronting Limitations

Samantha A. Armstrong, MD; Karine Tawagi, MD

September 14, 2026

Metastatic Non-Small Cell Lung Cancer 2026 UPDATE

September 11, 2026

The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing

All series

All Podcasts

Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD

ByJohn N. Allan, MD

July 30th 2026

John N. Allan, MD, discusses all things regarding fixed-duration regimens in CLL from a review of the most pivotal data for the topic.

Marlana M. Orloff, MD, the Alexander & Johnston Family Endowed Clinical Director in Uveal Melanoma, and associate professor at Thomas Jefferson University Hospital

Sequencing Systemic and Liver-Directed Therapy in HLA-A*02:01–Negative Metastatic Uveal Melanoma: With Marlana M. Orloff, MD

ByMarlana M. Orloff, MD

July 29th 2026

Dr Orloff discusses the distinct biology of uveal melanoma and why it has historically resisted systemic treatment.

Experts Bridge Oncology and Neurology to Catch LEMS Earlier in SCLC: With Misty D. Shields, MD, PhD; Triparna Sen, MD, PhD, MS; and Ditte Primdahl, MD

ByMisty D. Shields, MD, PhD,Triparna Sen, PhD,Ditte Primdahl, MD

July 28th 2026

Lung cancer and neurology experts discuss the ties between cancer-associated LEMS and small cell lung cancer, diagnostic tips, and management strategies.

FDA Approval Insights: Orca-T Raises the Bar for Allogeneic Transplants in Hematologic Malignancies: With Everett Meyer, MD, PhD

ByEverett Meyer, MD, PhD

July 28th 2026

Everett Meyer, MD, PhD, discusses the significance of the FDA approval of Orca-T for patients with hematologic malignancies.

ASCO 2026 ADC Data Clarify Some Strategies and Raise Further Questions for Breast Cancer Care: With Paolo Tarantino, MD, PhD

ByPaolo Tarantino, MD

July 27th 2026

Dr Tarantino discusses practice-informing data regarding antibody-drug conjugates in breast cancer that were presented at the 2026 ASCO Annual Meeting.

FDA Approval Insights: First-Line Sacituzumab Govitecan Plus Pembrolizumab for PD-L1+ TNBC: With Sara M. Tolaney, MD, MPH

BySara M. Tolaney, MD, MPH

July 27th 2026

Dr Tolaney discusses the FDA approval of first-line sacituzumab govitecan plus pembrolizumab for locally advanced or metastatic PD-L1–positive TNBC.

FDA Approval Insights: Orally Disintegrating Nilotinib Tablets for CML: With Jorge E. Cortes, MD; and Elias Jabbour, MD

ByJorge Cortes, MD,Elias Jabbour, MD

July 27th 2026

Dr Cortes and Dr Jabbour discuss the orally disintegrating tablet formulation of nilotinib and its June 2026 FDA approval for patients with CML.

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

July 24th 2026

OncLive On Air® CE

Joshua K. Sabari, MD, assistant professor in the Department of Medicine at NYU Grossman School of Medicine, and director of High Reliability Organization Initiatives at NYU Langone Health’s Perlmutter Cancer Center

Treat Early and Aggressively: Optimizing Small Cell Lung Cancer Management Across the Community Setting: With Joshua K. Sabari, MD

ByJoshua K. Sabari, MD

July 24th 2026

Joshua K. Sabari, MD, discusses the complexities of managing SCLC across both academic and community settings.

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

July 23rd 2026

OncLive On Air® CE

Sara Nunnery, MD, MSCI, breast medical oncologist, director, Breast Cancer Research, Tennessee Oncology in Nashville; Maelee Yang, MD, plastic surgeon, The Surgical Clinic; Odette Abou Ghanem, MD, assistant professor, plastic and reconstructive surgery, plastic and reconstructive surgeon, Vanderbilt University Medical Center

Post-Breast Cancer Reconstruction Options Center Patient Preferences and Oncologic Expertise: With Sara Nunnery, MD, MSCI; Maelee Yang, MD; and Odette Abou Ghanem, MD

BySara Nunnery, MD, MSCI,Maelee Yang, MD ,Odette Abou Ghanem, MD

July 21st 2026

Drs Nunnery, Yang, and Abou Ghanem discuss available breast reconstruction options following breast cancer surgery.

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

July 21st 2026

OncLive On Air® CE

DLBCL 2026 UPDATE

BySamantha A. Armstrong, MD,Karine Tawagi, MD

July 20th 2026

Two Onc Docs delivers a comprehensive, board-focused review of DLBCL for 2026, updating their prior coverage to reflect several recent practice changes.

Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC

July 20th 2026

OncLive On Air® CE

Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

July 17th 2026

OncLive On Air® CE

Neil D. Gross, MD, FACS, The University of Texas MD Anderson Cancer Center

Navigating Systemic Therapy Selection and Sequencing in Advanced CSCC: With Neil D. Gross, MD, FACS

ByNeil D. Gross, MD, FACS

July 17th 2026

Dr Gross discusses the key biological and clinical distinctions between cutaneous squamous cell carcinoma and basal cell carcinoma.

Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology

July 16th 2026

OncLive On Air® CE

Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2– Metastatic Breast Cancer—What the Latest Data Really Tell Us

July 15th 2026

OncLive On Air® CE

Cases and Conversations™: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

July 14th 2026

OncLive On Air® CE

RECITE Findings Highlight the Potential of Romiplostim to Preserve Chemotherapy Delivery in GI Cancer: With Gerald Soff, MD

ByGerald Soff, MD

July 13th 2026

Gerald Soff, MD, discusses the phase 3 RECITE trial, which evaluated romiplostim for the treatment of persistent chemotherapy-induced thrombocytopenia in patients with GI cancer.

Medical Crossfire®: Closing Clinical Practice Gaps in Hepatobiliary Cancer With Emerging Immunotherapies and Delivery Innovations

July 13th 2026

OncLive On Air® CE

Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

July 10th 2026

OncLive On Air® CE

FDA Approval Insights: Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma: With Alex Herrera, MD

ByAlex Herrera, MD

July 9th 2026

Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for untreated classical Hodgkin lymphoma.

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

July 9th 2026

OncLive On Air® CE

D. Ross Camidge, MD, PhD; Funda Meric-Bernstam, MD, department chair, Endowed Nellie B. Connally Chair in Breast Cancer, Department of Investigational Cancer Therapeutics, medical director, Khalifa Institute for Personalized Cancer Therapy, professor, breast surgical oncology, The University of Texas MD Anderson Cancer Center in Houston, regular member, Cancer Biology, University of Texas Houston Graduate School of Biomedical Sciences

How a Passion for Translational Research Fuses Surgery, Science, and Phase 1 Drug Development: With D. Ross Camidge, MD, PhD; and Funda Meric-Bernstam, MD

ByRoss Camidge, MD, PhD,Funda Meric-Bernstam, MD

July 8th 2026

This episode highlights Dr Meric-Bernstam's evolution from a science-focused student into a leader in precision oncology and early-phase drug development.

Sara Nunnery, MD, MSCI, breast medical oncologist, director, Breast Cancer Research, Tennessee Oncology; MinhTri Nguyen, MD, breast medical oncologist, assistant professor, lead faculty for Health Equity, Rush MD Anderson Cancer Center

ESR1 Mutations Steer the Oral SERD Story in Breast Cancer: With Sara Nunnery, MD, MSCI; and MinhTri Nguyen, MD

BySara Nunnery, MD, MSCI,MinhTri Nguyen, MD

July 7th 2026

Drs Nunnery and Nguyen discuss the emergence of the oral SERD giredestrant in hormone receptor–positive, HER2-negative breast cancer management.

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

July 7th 2026

OncLive On Air® CE

FDA Approval Insights: T-DXd for Early-Stage HER2+ Breast Cancer: With Charles E. Geyer, MD

ByCharles E. Geyer, MD

June 30th 2026

Charles E. Geyer, MD, discusses the FDA approvals of trastuzumab deruxtecan for the management of early-stage HER2-positive breast cancer.

Dissecting INDEPENDENCE Data and the Role of Luspatercept in Myelofibrosis-Associated Anemia: With Claire Harrison, MD

ByClaire Harrison, MD

June 30th 2026

Claire Harrison, MD, discusses data for luspatercept in myelofibrosis-associated anemia from the INDEPENDENCE trial.

SERENA-6 Splits the Breast Cancer Field on Switching Therapy Before Radiographic Progression: With Sara Nunnery, MD, MSCI; and Megan Kruse, MD

BySara Nunnery, MD, MSCI,Megan Kruse, MD

June 30th 2026

Drs Nunnery and Kruse discuss the controversy surrounding a biomarker-driven switch strategy in hormone receptor–positive, HER2-negative breast cancer.

Podcasts

Recent Episodes

All series

Oncology Unplugged With Dr Chandler Park

Pediatrics

Breast Cancer Briefing

Marvels in Medicine

One for Minutes With Markman

Talking Tumors

Ask Me Anything

Biomarker Consortium

State of the Science Summits

From Discovery to Delivery: Charting Progress in Gynecologic Oncology

OncLive on Air Powered by PER

Roundtable Discussions

Fellowship

Disparities

Rare Cancers

Women In Oncology

Conference Perspectives

OncClub

Oncology Expert Insights

FDA Approval Insights

Blood Club

Two Onc Docs

Cancer, Character, and Calling

How This Is Building Me

All Podcasts

Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD

Sequencing Systemic and Liver-Directed Therapy in HLA-A*02:01–Negative Metastatic Uveal Melanoma: With Marlana M. Orloff, MD

Experts Bridge Oncology and Neurology to Catch LEMS Earlier in SCLC: With Misty D. Shields, MD, PhD; Triparna Sen, MD, PhD, MS; and Ditte Primdahl, MD

FDA Approval Insights: Orca-T Raises the Bar for Allogeneic Transplants in Hematologic Malignancies: With Everett Meyer, MD, PhD

ASCO 2026 ADC Data Clarify Some Strategies and Raise Further Questions for Breast Cancer Care: With Paolo Tarantino, MD, PhD

FDA Approval Insights: First-Line Sacituzumab Govitecan Plus Pembrolizumab for PD-L1+ TNBC: With Sara M. Tolaney, MD, MPH

FDA Approval Insights: Orally Disintegrating Nilotinib Tablets for CML: With Jorge E. Cortes, MD; and Elias Jabbour, MD

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

Treat Early and Aggressively: Optimizing Small Cell Lung Cancer Management Across the Community Setting: With Joshua K. Sabari, MD

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

Post-Breast Cancer Reconstruction Options Center Patient Preferences and Oncologic Expertise: With Sara Nunnery, MD, MSCI; Maelee Yang, MD; and Odette Abou Ghanem, MD

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

DLBCL 2026 UPDATE

Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC

Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

Navigating Systemic Therapy Selection and Sequencing in Advanced CSCC: With Neil D. Gross, MD, FACS

Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology

Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2– Metastatic Breast Cancer—What the Latest Data Really Tell Us

Cases and Conversations™: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

RECITE Findings Highlight the Potential of Romiplostim to Preserve Chemotherapy Delivery in GI Cancer: With Gerald Soff, MD

Medical Crossfire®: Closing Clinical Practice Gaps in Hepatobiliary Cancer With Emerging Immunotherapies and Delivery Innovations

Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

FDA Approval Insights: Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma: With Alex Herrera, MD

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

How a Passion for Translational Research Fuses Surgery, Science, and Phase 1 Drug Development: With D. Ross Camidge, MD, PhD; and Funda Meric-Bernstam, MD

ESR1 Mutations Steer the Oral SERD Story in Breast Cancer: With Sara Nunnery, MD, MSCI; and MinhTri Nguyen, MD

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

FDA Approval Insights: T-DXd for Early-Stage HER2+ Breast Cancer: With Charles E. Geyer, MD

Dissecting INDEPENDENCE Data and the Role of Luspatercept in Myelofibrosis-Associated Anemia: With Claire Harrison, MD

SERENA-6 Splits the Breast Cancer Field on Switching Therapy Before Radiographic Progression: With Sara Nunnery, MD, MSCI; and Megan Kruse, MD

Trending on OncLive

Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC

Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma

Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma

FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma

Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma